Count G1 Therapeutics and Revolution Medicines among the biotechnology companies benefitting from a 2014 boom in venture capital funding that has spilled over into 2015.
Cancer-focused G1 in Research Triangle Park, North Carolina raised a $33m Series B VC funding round to advance its Phase...